Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation

Regional Anesthesia

Volumn 21, Issue 3, 1996, Pages 219-225

  Pierce, Pamela A ^a,c   Xie, Guo Xi ^b   Peroutka, Stephen J ^b   Levine, Jon D ^a  

^a UNIVERSITY OF SAN FRANCISCO   (United States)

^b Spectra Biomedical Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT receptors; neurogenic inflammation; peripheral C fibers; plasma extravasation; serotonin; sumatriptan

Indexed keywords

ADENYLATE CYCLASE; CAPSAICIN; NEUROPEPTIDE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; NEUROGENIC INFLAMMATION; NOCICEPTIVE RECEPTOR; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPINAL GANGLION; TRIGEMINAL NERVE;

ANIMALS; BASE SEQUENCE; CAPILLARY PERMEABILITY; GANGLIA, SPINAL; INFLAMMATION; MALE; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0029879703     PISSN: 0146521X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks: A review of controlled clinical trials. Cephalalgia 1993: 13: 238-244.
2. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology 1993: 43: S34-S38.
3. Buzzi MG, Moskowitz MA. The anti-migraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990: 99: 202-206.
4. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/5-HT1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991: 11: 165-168.
5. Bruinvels AT, Landwehrmeyer B, Moskowitz MA, Hoyer D. Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal ganglia. Eur J Pharmacol 1992: 227: 357-359.
6. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA. Selective 5-HT1Dα serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci U S A 1994: 91: 3666-3669.
7. Nozaki K, Boccalini P, Moskowitz MA. CP-93, 129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992: 106: 409-415.
8. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem 1993: 268: 23422-23426.
9. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 1993: 268: 18200-18204.
10. Hamblin MW, McGuffln RW, Metcalf MA, Dorsa DM, Merchant KM. Distinct 5-HT1B and 5-HT1D serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors. Mol Cell Neurosci 1992: 3: 578-587.
11. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991: 325: 316-321.
12. Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol 1992: 42: 549-557.
13. Carr J, Wilhelm DL. The evaluation of increased vascular permeability in the skin of guinea pigs. Aust J Exp Biol Med Sci 1964: 42: 511-522.
14. Barnes PJ, Belvisi MG, Rogers DP. Modulation of neurogenic inflammation: Novel approaches to inflammatory disease. Trends Pharmacol Sci 1990: 11: 185-189.
15. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res 1992: 583: 137-149.
16. Childers S. Opioid receptor-coupled second messenger systems. Life Sci 1991: 48: 1991-2003.
17. Green P, Levine JD. Delta- and kappa-opioid agonists inhibit plasma extravasation induced by bradykinin in the knee joint of the rat. Neuroscience 1992: 49: 129-133.
18. Green P, Basbaum AI, Levine JD. Sensory neuropeptide interactions in the production of plasma extravasation in the rat. Neuroscience 1992: 50: 745-749.
19. Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Bur J Pharmacol 1989: 163: 133-136.
20. Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG. Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci U S A 1993: 90: 2184-2188.
21. Albert PR, Zhou QY, VanTol HHM, Bunzow JR, Civelli O. Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptaminel A receptor gene. J Biol Chem 1990: 265: 5825-5832.
22. Maggi CA. The pharmacology of the efferent function of sensory nerves. J Auton Pharmacol 1991: 11: 173-208.
23. Donnerer J, Amann R. The inhibition of neurogenic inflammation. Gen Pharmacol 1993: 224: 519-529.
24. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993: 43: S16-S20.
25. Schwartzman RJ. Reflex sympathetic dystrophy and causalgia. Neurol Clin 1992: 10: 953-973.
26. Levine JD, Moskowitz MA, Basbaum AI. The contribution of neurogenic inflammation in experimental arthritis. J Immunol 1985: 135: 843s-847s.
27. Basbaum AI, Levine JD. The contribution of the nervous system to inflammation and inflammatory disease. Can J Physiol Pharmacol 1991: 69: 647-651.